	US 11,813,236 B2
	Substances for treatment of fatty liver-related conditions
Adil Mardinoglu, Gothenburg (SE); Jan Borén, Gothenburg (SE); and Mathias Uhlén, Lidingö (SE)
Assigned to SCANDIBIO THERAPEUTICS AB, Johanneshov (SE)
Filed by SCANDIBIO THERAPEUTICS AB, Johanneshov (SE)
Filed on Sep. 10, 2021, as Appl. No. 17/471,780.
Application 17/471,780 is a continuation of application No. 16/471,220, granted, now 11,141,396, previously published as PCT/SE2017/051306, filed on Dec. 20, 2017.
Claims priority of application No. 1651735-1 (SE), filed on Dec. 22, 2016.
Prior Publication US 2021/0401787 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/198 (2006.01); A61P 1/16 (2006.01); A61K 31/205 (2006.01); A61K 31/706 (2006.01)

CPC A61K 31/198 (2013.01) [A61K 31/205 (2013.01); A61K 31/706 (2013.01); A61P 1/16 (2018.01)]

21 Claims

1. A composition comprising:

A) serine, betaine, and/or glycine;

B) N-acetyl cysteine and/or cysteine;

C) L-carnitine; and

D) nicotinamide riboside and/or nicotinamide,

wherein the molar ratio of A) to D) is between 50:1 and 3:1 and the molar ratio of A) to B) is between 16:1 and 1.5:1.